Potential sources of interference on Abeta immunoassays in biological samples

Alzheimer's Research and Therapy

Volumn 4, Issue 5, 2012, Pages

  Vanderstichele, Hugo ^a   Stoops, Erik ^a   Vanmechelen, Eugeen ^a   Jeromin, Andreas ^b  

^a ADX NEUROSCIENCES   (Belgium)

^b Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AUTOANTIBODY; BIOLOGICAL MARKER; HETEROPHILE ANTIBODY; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; IMMUNIZATION; IMMUNOASSAY; PRIORITY JOURNAL; REVIEW;

EID: 84867790506     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt142     Document Type: Review

References (47)

1. Draft Guidance for Industry and Food and Drug Administration Staff-In vitro companion diagnostic devices. http://www.fda.gov/medicaldevices/ deviceregulationandguidance/guidancedocuments/ucm262292.htm
2. Biomarkers in Alzheimer's disease drug development. Blennow K, Nat Med 2010 16 1218 1222 10.1038/nm.2221 21052077
3. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ, Lancet Neurol 2010 9 119 128 10.1016/S1474-4422(09)70299-6 20083042
4. Amyloid beta (A) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). Lukiw WJ, Exp Opin Emerging Drugs 2012 17 43 60 10.1517/14728214.2012.672559 22439907
5. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K, Alzheimer's Dement 2012 8 65 73 10.1016/j.jalz.2011.07.004 23008501
6. Analytical aspects of molecular Alzheimer's disease biomarkers. Andreasson U, Vanmechelen E, Shaw L, Zetterberg H, Vanderstichele H, Biomarkers Med 2012 6 377 389 10.2217/bmm.12.44 22917140
7. Factors affecting the antigen-antibody reaction. Reverberi R, Reverberi L, Blood Transfus 2007 5 227 240 19204779
8. Standardization of measurement of -amyloid(1-42) in cerebrospinal fluid and plasma. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse M-A, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E, Amyloid 2000 7 245 258 10.3109/13506120009146438 11132093
9. Dynamic properties of pH-dependent structural organization of the amyloidogenic -protein (1-40). Rubinstein A, Lyubchenko YL, Sherman S, Prion 2009 3 31 43 10.4161/pri.3.1.8388 19372746
10. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsäter H, Anckarsäter R, Andreasen N, Zetterberg H, Andreasson U, Blennow K, Int J Alzheimers Dis 2010 pii 986310 20798852
11. A1-42 detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible A1-42 aggregation. Sancesario GM, Esposito Z, Nuccetelli M, Bernardini S, Sorge R, Martorana A, Federici G, Bernardi G, Sancesario G, Exp Neurol 2010 223 371 376 10.1016/j.expneurol.2009.07.028 19664624
12. The effect of pH on the aggregation of biotinylated antibodies and on the signal-to-noise observed in immunoassays utilizing biotinylated antibodies. Wadsley JJ, Watt RM, J Immunol Meth 1987 103 1 7 10.1016/0022-1759(87)90234-1 3116097
13. Inhibition of protein aggregation: supramolecular assemblies of arginine hold the key. Das U, Hariprasad G, Ethayathulla AS, Manral P, Das TK, Pasha S, Mann A, Ganguli M, Verma AK, Bhat R, Chandrayan SK, Ahmed S, Sharma S, Kaur P, Singh TP, Srinivasan A, PLos One 2007 11 1 9 18000547
14. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Levinson SS, Miller JJ, Clin Chim Acta 2002 325 1 15 10.1016/S0009-8981(02)00275-9 12367762
15. The war on heterophilic antibody interference. Bjerner J, Bormer OP, Nustad K, Clin Chem 2005 51 9 11 15613705
16. Interference from heterophilic antibodies in amyloid- oligomer ELISAs. Sehlin D, Söllvander S, Paulie S, Brundin RM, Ingelsson M, Lannfelt L, Pettersson FE, Englund H, J Alzheimers Dis 2010 21 1295 1301 21504116
17. Alzheimer's disease biomarkers: from concept to clinical utility. Vanderstichele H, De Meyer G, Shapiro F, Engelborghs S, De Deyn PP, Shaw LM, Trojanowski JQ, Biomarkers for early diagnosis of Alzheimer's Disease Nova Science Publishers, Inc., Galimberti D, Scarpini E, 2008 81 122 22989783
18. Improving immunoassay performance by antibody engineering. Stenman U-F, Clin Chem 2005 51 801 802 10.1373/clinchem.2005.049221 15855662
19. Human anti-animal antibody interferences in immunological assays. Kricka LJ, Clin Chem 1999 45 942 956 10388468
20. Evaluation of plasma A40 and A42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K, Neurobiol Aging 2010 31 357 367 10.1016/j.neurobiolaging. 2008.03.027 18486992
21. 42in human cerebrospinal fluid. Cullen VC, Fredenburg RA, Evans C, Conliffe PR, Solomon ME, AAPS J 2012 14 510 518 10.1208/s12248-012-9360-7 22552903
22. Measurement of A1-42 in cerebrospinal fluid is influenced by matrix effects. Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen N, Zetterberg H, Blennow K, J Neurochem 2012 120 325 333 10.1111/j.1471-4159.2011.07553.x 22023354
23. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. de Jager W, Prakken BJ, Bijlsma JWJ, Kuis W, Rijkers GT, J Immunol Methods 2005 300 124 135 10.1016/j.jim.2005.03.009 15896801
24. Immune complexes of auto-antibodies against A1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients. Henkel AW, Dittrich PS, Groemer TW, Lemke EA, Klingauf J, Klafki HW, Lewczuk P, Esselman H, Schwille P, Kornhuber J, Wiltfang J, Mol Psych 2007 12 601 610 10.1038/sj.mp.4001947 17279093
25. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M, Ann Neurol 2009 65 24 31 10.1002/ana.21475 19194878
26. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T, Nat Med 2007 13 1359 1362 10.1038/nm1653 17934472
27. 1-42deposition. Nagele RG, Clifford PM, Siu G, Levin EC, Acharya NK, Han M, Kosciuk MC, Venkataraman V, Zavareh S, Zarrabi S, Kinsler K, Thaker NG, Nagele EP, Dash J, Wang HY, Levitas A, J Alzheimers Dis 2011 25 605 622 21483091
28. Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrino J, Hardy J, Morgan D, DNA Cell Biol 2001 20 731 736 10.1089/10445490152717596 11788051
29. Elevation of -amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment. Storace D, Cammarata S, Borghi R, Sanguineti R, Giliberto L, Piccini A, Pollero V, Novello C, Caltagirone C, Smith MA, Boss P, Perry G, Odetti P, Tabaton M, Arch Neurol 2010 67 867 872 10.1001/archneurol.2010.137 20625095
30. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P, Exp Gerontol 2002 37 943 948 10.1016/S0531-5565(02)00029-3 12086704
31. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, Schade RF, Neurobiol Aging 2004 25 1023 1032 10.1016/j.neurobiolaging.2003.11.001 15212827
32. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T, Proc Natl Acad Sci USA 2009 106 12145 12150 10.1073/pnas.0904866106 19581601
33. Distinct patterns of anti amyloid- Antibodies in typical and atypical Alzheimer Disease. Dorothée G, Bottlaender M, Moukari E, de Souza LC, Maroy R, Corlier F, Colliot O, Chupin M, Lamari F, Lehéricy S, Dubois B, Sarazin M, Aucouturier P, Arch Neurol 2012 18 1 5
34. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. Li Q, Gordon M, Cao C, Ugen KE, Morgan D, BMC Neurosci 2007 8 22 10.1186/1471-2202-8-22 17374155
35. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. Gustaw KA, Garrett MR, Lee HG, Castellani RJ, Zagorski MG, Prakasam A, Siedlak SL, Zhu X, Perry G, Petersen RB, Friedland RP, Smith MA, J Neurochem 2008 106 1350 1356 10.1111/j.1471-4159.2008.05477.x 18485104
36. Anti - amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab. Panza F, Frisardi V, Imbimbo BP, Seripa D, Paris F, Santamato A, D'Onofrio G, Logroscino G, Pilotto A, Solfrizzi V, Curr Alzheimer Res 2011 8 808 817 10.2174/156720511798192718 21592055
37. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, Grundman M, Alzheimer Dis Assoc Disord 2010 24 198 203 10.1097/WAD. 0b013e3181c53b00 20505438
38. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Imbimbo BP, Ottonello S, Frisardi V, Solfrizzi V, Greco A, Seripa D, Pilotto A, Panza F, Expert Rev Clin Immunol 2012 8 135 149 10.1586/eci.11.93 22288451
39. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease. Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, Ieiri I, Siemers ER, Clin Neuropharmacol 2012 35 25 29 10.1097/WNF.0b013e31823a13d3 22134132
40. Gantenerumab for the treatment of Alzheimer's disease. Delrieu J, Ousset PJ, Vellas B, Expert Opin Biol Ther 2012 12 1077 1086 10.1517/14712598.2012. 688022 22583155
41. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L, Arch Neurol 2012 69 198 207 10.1001/archneurol.2011.1538 21987394
42. 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. Freeman GB, Lin JC, Pons J, Raha NM, J Alzheimers Dis 2012 28 531 541 22045481
43. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Muhs A, Hickman DT, Pihlgren M, Chuard N, Giriens V, Meerschman C, van der Auwera I, van Leuven F, Sugawara M, Weingertner MC, Bechinger B, Greferath R, Kolonko N, Nagel-Steger L, Riesner D, Brady RO, Pfeifer A, Nicolau C, Proc Natl Acad Sci USA 2007 104 9810 9815 10.1073/pnas.0703137104 17517595
44. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, Oertel W, Drugs 2010 70 513 528 10.2165/11533070-000000000-00000 20329802
45. Effect of immunotherapy with Bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E, for the AAB-001 201/202 Investigators, Arch Neurol 2012 69 1002 1010 10.1001/archneurol.2012.90 22473769
46. Safety, tolerability, and antibody response of active A immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A, Lancet Neurol 2012 11 567 650 10.1016/S1474-4422(12)70144-8 22710749
47. Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing. Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W, J Nutr Health Aging 2009 13 264 267 10.1007/s12603-009- 0070-5 19262965